Aquestive Therapeutics, Inc.
AQSTNASDAQHealthcare● Active
$3.93
$-0.21(-5.07%)
Market Cap$390275079
P/E Ratio—
52W High$7.55
52W Low$2.93
Aquestive Therapeutics, Inc. (AQST) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AQST · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.07
Est. -$0.14 · +50.0%
Revenue
$0.01B
Est. $0.01B · +32.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
AQST reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.10 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.14 | -$0.07 | +50.0% | $0.01B | $0.01B | +32.6% |
| ▼ Q1 FY2026 | Mar 4, 2026 | -$0.13 | -$0.26 | -100.0% | $0.01B | $0.01B | -2.0% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.11 | -$0.14 | -27.3% | $0.01B | $0.01B | -1.1% |
| ▲ Q3 FY2025 | Aug 11, 2025 | -$0.18 | -$0.14 | +22.2% | $0.01B | $0.01B | -18.0% |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.17 | -$0.24 | -41.2% | $0.01B | $0.01B | -28.7% |
| ▼ Q1 FY2025 | Mar 5, 2025 | -$0.14 | -$0.19 | -35.7% | $0.01B | $0.01B | -9.5% |
| ▼ Q4 FY2024 | Nov 4, 2024 | -$0.12 | -$0.13 | -8.3% | $0.01B | $0.01B | +3.2% |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.07
EPS Est.
-$0.14
EPS Surpr.
+50.0%
Revenue
$0.01B
Q1 FY2026
Mar 4, 2026Miss
EPS Actual
-$0.26
EPS Est.
-$0.13
EPS Surpr.
-100.0%
Revenue
$0.01B
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$0.14
EPS Est.
-$0.11
EPS Surpr.
-27.3%
Revenue
$0.01B
Q3 FY2025
Aug 11, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$0.18
EPS Surpr.
+22.2%
Revenue
$0.01B
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.24
EPS Est.
-$0.17
EPS Surpr.
-41.2%
Revenue
$0.01B
Q1 FY2025
Mar 5, 2025Miss
EPS Actual
-$0.19
EPS Est.
-$0.14
EPS Surpr.
-35.7%
Revenue
$0.01B
Q4 FY2024
Nov 4, 2024Miss
EPS Actual
-$0.13
EPS Est.
-$0.12
EPS Surpr.
-8.3%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.09 | $-0.08 | $-0.07 | 1 |
| Q3 FY2027 | $-0.10 | $-0.09 | $-0.07 | 1 |
| Q2 FY2027 | $-0.12 | $-0.11 | $-0.09 | 1 |
| Q1 FY2027 | $-0.13 | $-0.11 | $-0.10 | 1 |
| Q4 FY2026 | $-0.15 | $-0.13 | $-0.11 | 1 |
| Q3 FY2026 | $-0.15 | $-0.11 | $-0.06 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +50.0% | $4.16 | $4.13 | -0.72% |
| ▼ Q1 FY2026 | Mar 4, 2026 | -100.0% | $4.12 | $4.37 | +6.07% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -27.3% | $6.08 | $6.00 | -1.32% |
| ▲ Q3 FY2025 | Aug 11, 2025 | +22.2% | $3.90 | $3.86 | -1.03% |
| ▼ Q2 FY2025 | May 12, 2025 | -41.2% | $2.79 | $2.85 | +2.15% |
| ▼ Q1 FY2025 | Mar 5, 2025 | -35.7% | $2.73 | $2.79 | +2.20% |
| ▼ Q4 FY2024 | Nov 4, 2024 | -8.3% | $5.52 | $5.15 | -6.70% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +72.7% | $3.29 | $3.40 | +3.34% |
Q2 FY2026-0.72%
Report Date
May 13, 2026
EPS Beat/Miss
+50.0%
Price Before
$4.16
Price After
$4.13
Q1 FY2026+6.07%
Report Date
Mar 4, 2026
EPS Beat/Miss
-100.0%
Price Before
$4.12
Price After
$4.37
Q4 FY2025-1.32%
Report Date
Nov 5, 2025
EPS Beat/Miss
-27.3%
Price Before
$6.08
Price After
$6.00
Q3 FY2025-1.03%
Report Date
Aug 11, 2025
EPS Beat/Miss
+22.2%
Price Before
$3.90
Price After
$3.86
Q2 FY2025+2.15%
Report Date
May 12, 2025
EPS Beat/Miss
-41.2%
Price Before
$2.79
Price After
$2.85
Q1 FY2025+2.20%
Report Date
Mar 5, 2025
EPS Beat/Miss
-35.7%
Price Before
$2.73
Price After
$2.79
Q4 FY2024-6.70%
Report Date
Nov 4, 2024
EPS Beat/Miss
-8.3%
Price Before
$5.52
Price After
$5.15
Q3 FY2024+3.34%
Report Date
Aug 6, 2024
EPS Beat/Miss
+72.7%
Price Before
$3.29
Price After
$3.40
Avg Beat Reaction+0.53%
Avg Miss Reaction+0.48%
Beat Rate3 / 8 quarters
Largest Move-6.70% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AQST ends December
Aquestive Therapeutics, Inc. (AQST) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.07 — beating the analyst consensus of $-0.14 by +50.0%. The next AQST earnings date is expected around September 1, 2026.
Each quarter, investors track AQST earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AQST revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AQST's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AQST earnings · 5 questionsAquestive Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. AQST typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AQST historically reports after market close (AMC).
AQST earnings datewhen is AQST earningsAQST next earnings datewhen does AQST report earningsAQST earnings calendar
▸ Source: FMP · Aquestive Therapeutics, Inc. SEC filings · US GAAP · Aquestive Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026